Literature DB >> 17288873

Cyclooxygenase-2: a novel target in human solid tumors.

Maria Rosaria Raspollini1, Gian Luigi Taddei.   

Abstract

The enzyme cyclooxygenase-2, which is involved in the conversion of arachidonic acid-to-prostanoid synthesis, plays a key role in many inflammatory and proliferative reactions. Experimental data have shown that prostaglandins have a central action in therapeutic targeting not only in the treatment of many inflammatory diseases but also in several types of human cancers. Inhibitors of cyclooxygenase activity seem to protect against carcinoma development and show promise as chemopreventive agents and possible target therapies. Data support new treatments for patients with solid cancers tailored to the molecular characteristics of the individual tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17288873     DOI: 10.1007/s11912-007-0004-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  50 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

Authors:  A F Soriano; B Helfrich; D C Chan; L E Heasley; P A Bunn; T C Chou
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.

Authors:  Yoshimi Kakiuchi; Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Naoki Kawai; Masakazu Yasumaru; Arata Kimura; Masato Komori; Takanobu Irie; Eiji Miyoshi; Yutaka Sasaki; Norio Hayashi; Sunao Kawano; Masatsugu Hori
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.

Authors:  M R Raspollini; G Amunni; A Villanucci; V Boddi; G L Taddei
Journal:  Int J Gynecol Cancer       Date:  2005 Mar-Apr       Impact factor: 3.437

6.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors:  Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

7.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

8.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

9.  Significance of COX-2 expression in human renal cell carcinoma cell lines.

Authors:  Qinzhong Chen; Nobuo Shinohara; Takashige Abe; Takafumi Watanabe; Katsuya Nonomura; Tomohiko Koyanagi
Journal:  Int J Cancer       Date:  2004-03-01       Impact factor: 7.396

10.  Non-steroidal anti-inflammatory drugs and prostate cancer progression.

Authors:  A E Norrish; R T Jackson; C U McRae
Journal:  Int J Cancer       Date:  1998-08-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.